Michael Schotsaert
NIH Rank #4729
- R01 Holder
- Multi-Institutional
- Early Career
- Diverse Portfolio
NIH Funding · FY2024
Total Funding
$2.1M
Fiscal year 2024
Grants Awarded
4
Active NIH grants
National Rank
#4,729
Among 57,894 PIs
First NIH Award
2024
Year of first funding
Funding & rank history
NIH funding totals and national rank by fiscal year.
Single fiscal year on record (FY2024): $2.1M across 4 grants · National rank #4729.
Top grants by award amount
Michael Schotsaert's NIH grant portfolio, ranked by award amount.
- 5R44AI176894-02R447HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$953.5Kaward amount
- 5R01AI160706-03R01Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy$725.8Kaward amount
- 1R21AI180874-01R21Impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza virus infection$264.3Kaward amount
- 5R21AI176069-02R21Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity$204.8Kaward amount
Affiliations
Institutions that have administered grants for Michael Schotsaert.
Career milestones
Key NIH funding milestones over time.
- 2024First NIH Award7 Hills Pharma, LLC
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #4729
- 2024Entered Top 25% NationallyRanked #4729
- 2024Multi-Institutional ResearchAwards at 3 institutions
Related investigators
Other NIH-funded PIs frequently associated with Michael Schotsaert.
Explore further
Find collaborators for Michael Schotsaert
Search NIH-funded principal investigators by topic, department, or activity.
Open Find Collaborators →Check S10 eligibility at 7 Hills Pharma, LLC
Review past S10 Shared Instrumentation Grant awards and equipment categories.
Open S10 Eligibility Finder →Benchmark grant budgets
Compare median NIH grant budgets across departments, mechanisms, and years.
Open Grant Budget Benchmark →